NKX019

BIOLOGICAL4 trials

Conditions

Aggressive LymphomaAntineutrophil Cytoplasmic Antibody-Associated VasculitisB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaIdiopathic Inflammatory MyopathiesIndolent LymphomaLarge B-cell LymphomaLarge-cell Lymphoma

Phase 1

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruitingNCT05020678

Nkarta, Inc.Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia +7

Start: 2021-08-20End: 2038-12-01Target: 150Updated: 2026-04-20

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Enrolling by invitationNCT06518668

Hospital for Special Surgery, New YorkSystemic Lupus Erythematosus

Start: 2024-07-01End: 2040-12-01Target: 6Updated: 2026-06-22

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

RecruitingNCT06557265

Nkarta, Inc.Lupus Nephritis, Primary Membranous Nephropathy

Start: 2024-06-13End: 2027-04-01Target: 120Updated: 2026-06-04

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

RecruitingNCT06733935

Nkarta, Inc.Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis +1

Start: 2024-11-04End: 2028-10-01Target: 240Updated: 2026-08-07

Blood2024-11-056 citations

S261: FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

HemaSphere2023-08-019 citations

First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B‐cell malignancies

Hematological Oncology2023-06-0110 citations

902 NKX019, an off-the-shelf CD19 CAR-NK cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs

Regular and Young Investigator Award Abstracts2022-11-013 citations

NKX019

Sponsors

Conditions

Phase 1

Related Papers